The Rare Disease Action Forum shared with the Swiss Federal Office of Public Health its statement on the public consultation on the revision of the Federal Health Insurance Act concerning package 2 of the cost containment measures. The RDAF highlighted measures that could potentially affect patients with rare diseases and stressed that any implementation would need to take into consideration the specificities of rare diseases and their therapies. It is important to take account of indirect costs of a disease for those affected and their families, and that access to therapies can be achieved as quickly as possible. Click here to open the RDAF statement.